Waterloo grads invest time and money in COVID-19 vaccine solutions
SARS-CoV-2, the strain of coronavirus that causes COVID-19, has continued to evolve at a rapid pace in the last two years, leading to the emergence of new, tougher variants and a surge in breakthrough infections of fully vaccinated and boosted people around the world.
As a result, there is a pressing need to develop new, safe, cost-effective vaccines that provide broader coverage and are accessible to people everywhere. Fortunately, that is entirely possible thanks to trailblazing startup Refana, which has a strong connection to the engineering faculty, dating back to the 1980s.